Freenome (NASDAQ:FRNM) Raised to “Strong-Buy” at TD Cowen

Freenome (NASDAQ:FRNM) was upgraded by equities researchers at TD Cowen to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. BTIG Research assumed coverage on Freenome in a research note on Monday. They set a “buy” rating and a $17.00 price objective for the company. Leerink Partners assumed coverage on Freenome in a report on Friday, August 14th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, Jefferies Financial Group assumed coverage on Freenome in a research note on Monday. They issued a “buy” rating and a $17.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $17.25.

Freenome Price Performance

FRNM opened at $13.63 on Tuesday. The firm has a market cap of $111.22 million, a price-to-earnings ratio of -227.13 and a beta of 0.35. Freenome has a 52 week low of $9.97 and a 52 week high of $14.26.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.